You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

LANSOPRAZOLE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lansoprazole, and when can generic versions of Lansoprazole launch?

Lansoprazole is a drug marketed by Ajanta Pharma Ltd, Alkem Labs Ltd, Breckenridge, Chartwell Molecular, Dr Reddys Labs Ltd, Glenmark Pharms Inc, Hetero Labs Ltd Iii, Inventia, Krka Tovarna Zdravil, Lannett Co Inc, Mylan, Mylan Pharms Inc, Natco, Natco Pharma Ltd, Perrigo R And D, Sandoz, Sun Pharm, Teva Pharms, Wockhardt, Xiromed, Zydus Hlthcare, Ani Pharms, Aurobindo Pharma Ltd, Dexcel, Dr Reddys, Teva Pharms Usa, Zydus Pharms, and Rising. and is included in thirty-three NDAs. There is one patent protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in LANSOPRAZOLE is amoxicillin; clarithromycin; lansoprazole. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; lansoprazole profile page.

DrugPatentWatch® Generic Entry Outlook for Lansoprazole

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for LANSOPRAZOLE
Drug Prices for LANSOPRAZOLE

See drug prices for LANSOPRAZOLE

Drug Sales Revenue Trends for LANSOPRAZOLE

See drug sales revenues for LANSOPRAZOLE

Recent Clinical Trials for LANSOPRAZOLE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jeil Pharmaceutical Co., Ltd.Phase 4
Daejeon St. Mary's hospitalPhase 4
Nanfang Hospital of Southern Medical UniversityPhase 4

See all LANSOPRAZOLE clinical trials

Pharmacology for LANSOPRAZOLE
Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors
Physiological EffectInhibition Gastric Acid Secretion
Medical Subject Heading (MeSH) Categories for LANSOPRAZOLE
Paragraph IV (Patent) Challenges for LANSOPRAZOLE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PREVACID Delayed-release Orally Disintegrating Tablets lansoprazole 15 mg and 30 mg 021428 1 2006-12-27
PREVACID Delayed-release Pellets/Capsules lansoprazole 15 mg and 30 mg 020406 2005-12-05

US Patents and Regulatory Information for LANSOPRAZOLE

LANSOPRAZOLE is protected by one US patents.

Patents protecting LANSOPRAZOLE

Orally disintegrating compositions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd LANSOPRAZOLE lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 207167-001 Mar 28, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms LANSOPRAZOLE lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 077255-002 Nov 10, 2009 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms Usa LANSOPRAZOLE lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208784-002 Sep 21, 2017 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys LANSOPRAZOLE lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 210465-002 Feb 1, 2021 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zydus Pharms LANSOPRAZOLE lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 200816-001 Nov 27, 2018 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Sandoz LANSOPRAZOLE lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 090331-002 Apr 23, 2010 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Wockhardt LANSOPRAZOLE lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 202176-001 Sep 14, 2012 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LANSOPRAZOLE

See the table below for patents covering LANSOPRAZOLE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3288556 COMPOSITIONS À DÉSINTÉGRATION PAR VOIE ORALE (ORALLY DISINTEGRATING COMPOSITIONS) ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2016174664 ⤷  Try a Trial
Israel 255048 הרכבים המתפוררים בפה (Orally disintegrating compositions) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LANSOPRAZOLE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0174726 93C0021 Belgium ⤷  Try a Trial PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
0328535 96C0021 Belgium ⤷  Try a Trial PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
1129088 2014/008 Ireland ⤷  Try a Trial PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.